Publications by authors named "A Giana"
Introduction And Importance: Patients with phenylketonuria (PKU) exhibit a high incidence of obesity. Currently, bariatric surgery remains the most effective long-term treatment for obese patients. However, limited data regarding the applicability of bariatric surgery to obese patients with PKU have been reported in the literature.
View Article and Find Full Text PDFIntroduction: Astrocytes are involved in Parkinson's disease (PD) where they could contribute to α-Synuclein pathology but also to neuroprotection via α-Synuclein clearance. The molecular signature underlying their dual role is still elusive. Given that vitamin D has been recently suggested to be protective in neurodegeneration, the aim of our study was to investigate astrocyte and neuron vitamin D pathway alterations and their correlation with α-Synuclein aggregates (ie, oligomers and fibrils) in human brain obtained from PD patients.
View Article and Find Full Text PDFLumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion.
J Endocrinol Invest
October 2021
Purpose: The question whether the new cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs aimed at restoring CFTR protein function might improve glucose metabolism is gaining attention, but data on the effect of lumacaftor/ivacaftor treatment (LUMA/IVA) on glucose tolerance are limited. We evaluated the variation in glucose metabolism and insulin secretion in CF patients homozygous for Phe508del CFTR mutation after one-year treatment with LUMA/IVA in comparison to patients with the same genotype who did not receive such treatment.
Methods: We performed a retrospective case-control study on 13 patients with a confirmed diagnosis of CF, homozygous for the Phe508del CFTR mutation, who received LUMA/IVA for one year (cases) and 13 patients with identical genotype who did not receive this treatment (controls).
Article Synopsis
- Patients with cystic fibrosis (CF) often require Pancreatic Enzyme Replacement Therapy (PERT) to digest dietary fats, but determining the right dose for each meal can be difficult.
- This study tested a mobile app that supports PERT dosing based on individual food types and in vitro digestion research, with patients tracking their diet and enzyme use over a month.
- Results showed that while overall fat absorption remained stable, the app helped narrow the range of PERT doses needed, and children with initially low fat absorption saw significant improvements after following the app's dosing recommendations.
Background: Parkinson's disease (PD) patients have lower levels of serum 25-hydroxyvitamin D (25(OH)D) than the general population. Previous studies have suggested a negative association between 25(OH)D and clinical features of PD, but the data are inconsistent.
Materials And Methods: We conducted a cross-sectional, observational study.